After 8 years of planning, the first clinical trial of an HIV vaccine in Africa has been launched in Uganda.
The trial is being conducted at the Joint Clinical Research Center in Kampala and at the Uganda Virus Research Institute in Entebbe. It will evaluate the safety and durability of immune response to a vaccine known as ALVAC vCP205, which is based on an attenuated canarypox virus. The vaccine contains only three HIV genes, rendering it incapable of causing HIV infection.
Voelker R. HIV Vaccine Trial in Africa. JAMA. 1999;281(10):889. doi:10.1001/jama.281.10.889
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: